C-Ray Therapeutics is a global CRDMO dedicated to advancing the development and manufacturing of innovative radiopharmaceuticals. We provide end-to-end solutions—from process development, preclinical evaluation, and IND-enabling studies to clinical supply and commercial-scale cGMP production—supported by a robust global logistics network.

Our 28,000 m² state-of-the-art R&D and manufacturing facilities are equipped with the highest Class A Radiation Safety License, enabling large-scale production of 30+ radioisotopes. Our integrated preclinical center supports both small and large animal studies, including in vivo imaging, biodistribution, and dosimetry analysis.

To date, we have successfully executed over 60 CRDMO projects worldwide, including preclinical and molecular imaging studies, CDMO collaborations, and multiple programs advancing through IND, IIT, and clinical supply stages—one of which has progressed to a Phase III clinical trial.

A core strength of C-Ray is our stable, diversified radionuclide supply chain. We play a leading role in securing access to critical isotopes, including Ac-225, and have supported 16 Ac-225–labeled programs globally.

By building an open “production–academia–research–application” platform, C-Ray is accelerating the clinical translation of integrated diagnostic and therapeutic solutions. Our vision is to set the global benchmark for innovation, reliability, and industrial transformation in the radiopharmaceutical field.

C-Ray Therapeutics

Org chart

Teams

Offices